A detailed history of Johnson Financial Group, Inc. transactions in Genmab A/S stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 215 shares of GMAB stock, worth $4,800. This represents 0.0% of its overall portfolio holdings.

Number of Shares
215
Previous 215 -0.0%
Holding current value
$4,800
Previous $6,000 16.67%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$26.43 - $32.77 $396 - $491
-15 Reduced 6.52%
215 $6,000
Q4 2023

Feb 09, 2024

SELL
$27.94 - $35.44 $27,800 - $35,262
-995 Reduced 81.22%
230 $7,000
Q3 2023

Nov 14, 2023

BUY
$35.27 - $42.24 $43,205 - $51,744
1,225 New
1,225 $43,000

Others Institutions Holding GMAB

About GENMAB A/S


  • Ticker GMAB
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 658,292,992
  • Market Cap $14.7B
  • Description
  • Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphoc...
More about GMAB
Track This Portfolio

Track Johnson Financial Group, Inc. Portfolio

Follow Johnson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.